Peptide Therapy — Virginia Beach
Peptides Work. Most Clinics Have No Idea Which Ones — Or Why.
Every hormone and wellness clinic in Hampton Roads now offers peptide therapy. Walk into any of them and you will leave with Sermorelin or PT-141 — because those are the two peptides on the menu. Your biology had nothing to do with it.
Peptide therapy is one of the most powerful tools in precision medicine. It is also one of the most misused — not because practitioners are careless, but because prescribing peptides without a diagnostic framework is essentially guessing with a molecule.
At The Johnson Center, no peptide protocol begins without a complete picture of your cellular function. The GH axis. Mitochondrial efficiency. Inflammatory load. Gut integrity. Cognitive signaling. We identify where the communication failures are — and then we select the peptides that address those specific failures. In sequence. With monitoring. From pharmacies we trust.
Dr. Barbara Johnson, MD — 30+ years clinical medicine, surgical background, functional medicine and PNI
Serving Virginia Beach, Blacksburg, and telemedicine patients across Virginia
The Core Problem
Peptide therapy is one of the most powerful tools in precision medicine. It is also one of the most misused.
Not because practitioners are careless, but because prescribing peptides without a diagnostic framework is essentially guessing with a needle.
The Problem
Why Most Peptide Therapy Underdelivers
A menu is not a protocol.
The Virginia Beach peptide market has a structural problem. Practices list peptides the way a restaurant lists specials. You describe your symptoms. They match a peptide to the symptom. You leave with an injection kit and a vague promise about energy and recovery.
The problem isn't the peptides. Peptides are extraordinary molecules. The problem is the absence of clinical logic connecting your biology to the compound you're injecting.
Consider what determines whether Sermorelin will actually work for you: your baseline IGF-1, the integrity of your pituitary GH release pattern, whether your cortisol rhythm is blunted in a way that suppresses GH secretion regardless of stimulation, whether mitochondrial insufficiency is limiting downstream utilization of any GH increase you produce. A clinic that checks your testosterone and prescribes Sermorelin is skipping the entire diagnostic chain that determines whether that peptide will produce a clinical result.
This is why patients arrive at our practice having tried peptide therapy elsewhere with partial results or none at all. The peptide wasn't wrong. The diagnostic foundation wasn't there.
The Principle
A peptide is a cellular messenger. It carries a specific instruction to a specific receptor system. If the cellular environment receiving that message is compromised — by mitochondrial dysfunction, inflammatory overload, HPA dysregulation, or nutrient depletion — the message degrades before it arrives. Fixing the messenger without fixing the environment is incomplete medicine.
The Diagnostic Protocol
How We Select Peptides — Not From a Menu
Before a single peptide is prescribed, we run a comprehensive cellular assessment. This is what separates a protocol from a menu. We are looking for four things:
Where is cellular energy failing?
The Organic Acids Test maps mitochondrial efficiency, Krebs cycle function, neurotransmitter metabolism, and oxidative stress markers. This tells us whether the cell itself has the energy substrate to respond to peptide signaling — and which metabolic pathways are most compromised. This is the foundation of everything that follows.
Which hormonal axes are disrupted?
The GH/IGF-1 axis governs the primary GH secretagogue peptides (Sermorelin, Tesamorelin). The HPA axis governs cortisol rhythm, which directly affects GH release patterns and peptide receptor sensitivity. Sex hormones affect tissue repair signaling. We map all axes before recommending anything that touches hormonal biology.
What is the inflammatory and gut integrity picture?
Systemic inflammation degrades hormone receptor sensitivity, suppresses mitochondrial function, and accelerates cellular aging. For patients whose primary presentation is fatigue, brain fog, or hormone resistance, gut permeability is frequently the upstream problem. We assess inflammatory markers, gut permeability directly via Larazotide-relevant markers, and intestinal integrity before deploying gut or repair peptides.
What is the cognitive and neurological picture?
Cognitive peptides like Dihexa and PE-22-28 are considered in the context of neurotransmitter and BDNF data from the OAT, the HPA pattern (cortisol suppresses cognitive function directly), and the clinical cognitive presentation. We do not prescribe cognitive peptides as a first-line intervention — most cognitive symptoms in our population are downstream effects of fixable upstream problems.
The Sequence
Cellular energy support comes first. Then hormonal stabilization. Then targeted peptide deployment. Peptides amplify a functional system — they do not build one. The sequence is the protocol.
The Peptides We Prescribe
We Organize by Biological System — Not by Symptom
We currently prescribe ten peptides across five categories. Selection for any individual patient is based entirely on diagnostic findings.
Quick Reference: Peptide Categories at a Glance
| Category | Peptide(s) | Primary Mechanism | Key Indications | Diagnostic Trigger |
|---|---|---|---|---|
| GH Axis | Sermorelin, Tesamorelin | Stimulates pulsatile pituitary GH release; does not introduce exogenous GH | Poor recovery, muscle loss, body composition, sleep disruption, visceral fat | Low IGF-1; IGFBP-3 below range; GH-axis decline pattern |
| Mitochondrial / Metabolic | SS-31, 5-Amino 1MQ | SS-31: reduces mitochondrial ROS, restores ETC efficiency. 5-Amino 1MQ: inhibits NNMT, raises NAD+, restores metabolic flexibility | Cellular energy failure, exercise intolerance, metabolic dysfunction, biological age acceleration | CDR pattern on OAT; mitochondrial insufficiency; age-wave biology (44/60) |
| Gut Integrity & Repair | Larazotide, GHK-Cu | Larazotide: blocks zonulin/tight junction pathway. GHK-Cu: promotes collagen synthesis, tissue repair, anti-inflammatory gene activation | Gut permeability, systemic inflammation, impaired tissue healing, oxidative damage | Gut permeability markers on OAT or GI testing; elevated inflammation; high oxidative stress |
| Cognitive & Neurological | Dihexa, PE-22-28 | Dihexa: amplifies BDNF via HGF pathway. PE-22-28: modulates TREK-1 channel; antidepressant and cognitive mechanism | Executive function decline, brain fog, motivational failure, persistent cognitive symptoms after upstream optimization | Neurotransmitter insufficiency on OAT; persistent symptoms post-optimization; HPA-driven suppression |
| Vitality, Joint & Sexual Health | PT-141, Pentosan | PT-141: central melanocortin receptor agonist for sexual arousal/desire. Pentosan: chondroprotective, anti-inflammatory, cartilage matrix preservation | Libido loss unresolved by hormones (PT-141); joint pain, cartilage degeneration, connective tissue demands (Pentosan) | Failed hormonal intervention for sexual health; joint inflammation or degeneration markers; high-load lifestyle demands |
Swipe to see full table →
Regulatory Context
The 2026 FDA Peptide Reclassification — What It Actually Means
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 peptides previously restricted under the FDA's Category 2 list would be reclassified to Category 1 — restoring legal access through licensed compounding pharmacies under a physician's prescription.
What this means in practice: compounds that had been pushed into regulatory gray areas — and in many cases into unregulated gray-market sourcing — are being returned to the regulated physician-prescribed, pharmacy-compounded pathway where they belong.
Category 1 vs. Category 2 — The Distinction That Matters
Category 1 compounds can be legally compounded by a licensed pharmacy under a physician's prescription. This is the standard pathway for compounded medications in the United States — the same pathway used for bioidentical hormones, custom-dose thyroid medications, and other compounded pharmaceuticals.
Category 2 compounds were flagged by the FDA as requiring additional evaluation before compounding could continue. During the restriction period, some practices suspended these protocols entirely. Others directed patients to unregulated sources. The reclassification restores the regulated pathway.
The peptides The Johnson Center currently prescribes were not affected by the prior restriction period in terms of our clinical protocols. What the reclassification changes is the regulatory landscape for additional compounds that we are now preparing to add to our formulary — compounds like CJC-1295, Ipamorelin, BPC-157, and Thymosin Alpha-1 that have strong clinical evidence and that our patients have been asking about.
The sourcing standard and clinical oversight framework at The Johnson Center have not changed. We prescribe exclusively through FDA-registered compounding pharmacies meeting USP 797 and 795 standards. The reclassification expands what we can prescribe through that framework — it does not change the framework itself.
Sourcing Standards
Why Sourcing Is Not a Minor Detail
The 2023 FDA restrictions on certain compounded peptides created an unintended consequence: patients who had been receiving these compounds through legitimate physician-pharmacy channels were suddenly cut off. Many turned to the only sources still available — online vendors selling peptides labeled "for research use only" and informal distribution through fitness and wellness networks.
These sources are not held to pharmaceutical or compounding pharmacy quality standards. The risks they introduce are separate from whatever the peptide itself does — they are manufacturing and quality risks with real clinical consequences:
Unregulated Sourcing Risks
- •
Endotoxin contamination — bacterial byproducts that trigger systemic inflammatory response when injected
- •
Heavy metal content — arsenic, lead, mercury at levels that would fail pharmaceutical testing
- •
Residual solvents from manufacturing — organic compounds that are toxic at injection-relevant doses
- •
Microbial contamination — bacteria, fungi, or viral particles that bypass the immune system when injected subcutaneously
- •
Peptide concentration mismatch — the stated dose on the label does not match the actual peptide content in the vial
The 2026 reclassification is intended to close this gap — restoring access to properly regulated, physician-prescribed, pharmacy-compounded peptides. But the reclassification does not retroactively make a gray-market peptide safe. If you are currently using peptides from a non-prescription source, the compound itself may be legitimate. The question is whether the manufacturing, testing, and quality control behind that specific vial meets the standard you would expect for something you are injecting into your body.
Our Sourcing Standard
The Johnson Center prescribes exclusively through FDA-registered compounding pharmacies that meet USP 797 (sterile compounding) and USP 795 (non-sterile compounding) standards. Every compound is third-party tested for potency, sterility, endotoxins, and particulate matter. We discuss sourcing openly with every patient — because if you are going to inject a peptide, you should know exactly where it came from and what quality controls it passed.
Physician-Led
Why Physician-Led Peptide Therapy Matters
Most peptide therapy in Virginia Beach is delivered by physician assistants, nurse practitioners, or through online telehealth platforms with minimal oversight. This matters for two reasons.
Reason 1: Peptides interact with complex biological systems.
GH secretagogues affect the HPA axis. PT-141 acts on hypothalamic melanocortin receptors. Dihexa amplifies BDNF signaling at a potency level that requires understanding the downstream effects. Larazotide modulates tight junction permeability with systemic inflammatory implications. A provider who does not have the diagnostic depth to evaluate these systems before prescribing is operating without a complete picture of potential interactions.
This is not a safety indictment of every PA or NP in the market. It is a statement about diagnostic infrastructure. At The Johnson Center, every peptide protocol is designed by a physician with 30+ years of clinical experience, including a surgical background in which understanding systemic interactions was not optional.
Reason 2: The protocol is the treatment — not the peptide.
Peptides do not work in isolation. The clinical outcome depends on what you are combining them with, what you are addressing at the same time, and in what sequence. A GH secretagogue prescribed without addressing the cortisol rhythm that is suppressing GH release will underperform. Larazotide prescribed without addressing the upstream dysbiosis driving zonulin activation treats the permeability without solving the cause. PE-22-28 prescribed for brain fog before the HPA and mitochondrial picture has been assessed may be treating a symptom whose root is two steps upstream. Designing a complete protocol — not just selecting a compound — requires a physician who has built the diagnostic picture comprehensively.
Dr. Barbara Johnson
I did not add peptide therapy to my practice because it became trendy. I incorporated it because the research on mitochondrial peptides, GH axis restoration, gut integrity compounds, and cognitive signaling maps directly onto the cellular energy framework I have built my clinical approach around. These are not add-ons. In a correctly sequenced protocol, they are force multipliers for everything else we are doing.
Is This For You
Peptide Therapy at The Johnson Center May Be Appropriate If:
We see patients at our Virginia Beach and Blacksburg locations. Telemedicine follow-up is available throughout Virginia for established patients.
You have tried peptides elsewhere and felt partial improvement — or nothing — and want to understand why
You are in your 40s or 50s and experiencing declining energy, recovery, cognitive sharpness, or body composition that does not respond to lifestyle optimization
You have been told your labs are normal but your performance and vitality are clearly not
You are a high-performing executive or athlete who needs your cellular machinery to work at a level that supports the demands you place on it
You have a complex clinical picture — hormone dysregulation, fatigue, gut issues, cognitive symptoms — and you want a protocol that addresses all of it as a system
You want to understand the mechanism behind what you are taking, not just be handed a vial and a dosing schedule
You are currently purchasing peptides from a non-prescription source and want to transition to a physician-supervised, pharmacy-grade protocol
You are a man in your late 40s or 50s experiencing declining testosterone, recovery failure, or body composition changes and want to know whether peptide therapy belongs in your protocol
Peptide Therapy That Starts With Your Biology — Not a Menu.
Comprehensive cellular assessment. Physician-designed protocol. Ten peptides across five categories, sourced from licensed compounding pharmacies, deployed in sequence, based on your diagnostic picture.
Virginia Beach | Blacksburg | Telemedicine across Virginia
Expanding Our Formulary
What's Coming as the FDA Completes Reclassification
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 peptides previously restricted under the FDA's Category 2 list would be restored to legal compounding status. The formal updated guidance is expected within weeks of that announcement.
We are listing these here for one reason: transparency. Patients who have been accessing these compounds through unregulated sources deserve to know that a physician-supervised, pharmacy-grade option is coming. The reclassification does not make a gray-market peptide retroactively safe — but it does restore the regulated pathway that should have been available all along.
Growth Hormone Axis
CJC-1295Coming Soon
A long-acting GHRH analog with a significantly extended half-life compared to Sermorelin. Produces sustained GH elevation rather than a discrete pulse — expanding the GH axis protocol options for patients who need more continuous stimulation. Will be combined with Ipamorelin for patients whose diagnostic picture calls for enhanced GH release with cortisol and prolactin sparing.
IpamorelinComing Soon
A selective GH secretagogue that stimulates GH release without significantly raising cortisol or prolactin — the cleanest GH pulse stimulator in the category. Particularly appropriate for HPA-sensitive patients where cortisol elevation is a clinical concern. Will be used as a standalone and in CJC-1295/Ipamorelin combined protocols.
Tissue Repair and Gut Healing
BPC-157Coming Soon
Body Protection Compound-157 — a pentadecapeptide derived from human gastric juice with one of the broadest biological action profiles in the peptide category. Promotes angiogenesis, accelerates tissue repair, reduces systemic inflammation, protects gut lining integrity, and supports the blood-brain barrier. Over 180 PubMed citations. With Larazotide already in our formulary addressing tight junction regulation, BPC-157 adds mucosal healing and systemic repair capacity to the gut integrity protocol.
TB-500 (Thymosin Beta-4)Coming Soon
A tissue repair peptide that supports cell migration and healing through actin regulation, anti-inflammatory signaling, and promotion of new cell growth. Works synergistically with BPC-157 in musculoskeletal and systemic repair protocols. Directly relevant for high-performing patients with injury history, recovery failure, or significant connective tissue demands.
KPVComing Soon
A tripeptide (Lys-Pro-Val) derived from alpha-MSH with potent anti-inflammatory and gut mucosal protective properties. Acts directly on intestinal epithelial cells and immune cells to reduce inflammatory cytokine production. In patients with IBD-adjacent presentations, significant mucosal inflammation, or systemic inflammatory burden with a clear gut origin, KPV addresses a layer that Larazotide (tight junction regulation) and BPC-157 (mucosal repair) do not fully cover.
Mitochondrial and Metabolic
MOTS-CComing Soon
A mitochondrial-derived peptide encoded in the mitochondrial genome that activates AMPK — the master metabolic regulator — and stimulates mitochondrial biogenesis. Adding MOTS-C to our existing SS-31 and 5-Amino 1MQ protocols creates a three-compound mitochondrial tier that addresses ROS reduction (SS-31), NAD+ restoration (5-Amino 1MQ), and mitochondrial biogenesis (MOTS-C). No practice in Virginia Beach is working at this level of mitochondrial specificity.
AOD-9604Coming Soon
A fragment of the GH molecule that retains the fat metabolism effects of growth hormone without the growth-promoting or insulin-sensitizing effects of full GH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) through a beta-3 adrenergic receptor mechanism. Relevant for patients with persistent visceral adiposity or metabolic inflexibility who are already on GH axis protocols and need targeted metabolic support.
Immune Modulation
Thymosin Alpha-1Coming Soon
A thymic peptide with over 200 published studies since 2021, many driven by renewed research interest following COVID-19. Enhances T-cell maturation and function, supports immune surveillance, and modulates inflammatory tone without overstimulating immune response — a critical distinction for patients with autoimmune-adjacent presentations or chronic inflammatory burden. For patients presenting with post-viral fatigue, recurrent illness, or elevated inflammatory markers without clear infectious source, Thymosin Alpha-1 addresses a biological layer that no compound in our current formulary reaches.
Cognitive and Neurological
SemaxComing Soon
A synthetic analog of ACTH that modulates dopaminergic and serotonergic systems and has been studied for cognitive enhancement, neuroprotection, and anxiety reduction. Works through a mechanism distinct from PE-22-28 — primarily via BDNF upregulation and monoamine modulation. Adding Semax to the cognitive category gives us two mechanistically different tools for patients with complex neurological presentations.
SelankComing Soon
A synthetic analog of tuftsin with anxiolytic, nootropic, and immune-modulatory properties. Unlike conventional anxiolytics, Selank does not produce sedation, dependence, or tolerance. It modulates the GABAergic system and has demonstrated effects on memory consolidation, stress response regulation, and HPA axis normalization. For patients whose cognitive symptoms are significantly anxiety-driven or whose HPA dysregulation has not fully normalized with cortisol-targeted protocols, Selank provides a precision tool that bridges the cognitive and immune categories.
When These Become Available
We will update this page and notify established patients when the formal FDA guidance is published and our pharmacy partners confirm compliant supply. If you are currently accessing any of these compounds through non-prescription sources, we encourage you to schedule a consultation now — so that when the regulated pathway opens, your protocol is already built on a complete diagnostic picture rather than starting from zero.
Schedule a ConsultationFrequently Asked Questions